Allspring Global Investments Holdings LLC acquired a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,797 shares of the medical instruments supplier’s stock, valued at approximately $31,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its holdings in shares of Harvard Bioscience by 193.9% during the second quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock worth $649,000 after buying an additional 150,218 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Harvard Bioscience by 3.2% in the 4th quarter. New York State Common Retirement Fund now owns 142,460 shares of the medical instruments supplier’s stock valued at $762,000 after acquiring an additional 4,463 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Harvard Bioscience by 38.7% during the 1st quarter. BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock worth $322,000 after purchasing an additional 21,183 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock worth $9,125,000 after purchasing an additional 49,576 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Harvard Bioscience in the first quarter valued at $54,000. Institutional investors and hedge funds own 80.87% of the company’s stock.
Insider Buying and Selling at Harvard Bioscience
In other news, CEO James W. Green bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The shares were acquired at an average cost of $2.91 per share, with a total value of $29,100.00. Following the transaction, the chief executive officer now owns 3,111,091 shares of the company’s stock, valued at approximately $9,053,274.81. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 9.00% of the stock is owned by company insiders.
Harvard Bioscience Stock Performance
Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.06). Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. The company had revenue of $23.10 million for the quarter, compared to analysts’ expectations of $29.91 million.
About Harvard Bioscience
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
Read More
- Five stocks we like better than Harvard Bioscience
- The How and Why of Investing in Gold Stocks
- Why Block’s Key Components Make It a Solid Investment Choice
- The Basics of Support and Resistance
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report).
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.